12 April 2018 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Insulin glargine with lixisenatide (Soliqua)
  
• Abiraterone acetate (Zytiga)
  
• Niraparib tosylate monohydrate (Zejula)
  
• Everolimus (Votubia)
  
• Cyclopentolate (Skiakol)
  
• Glycerol phenylbutyrate (Revicti)
  
• Ursodeoxycholic acid (Delursan)
  

Read TC agenda [French]